Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 5th Floor 36 Dame Street, Dublin, Ireland

dayton91 Mar. 21 at 6:17 PM

$AMRN Big thanks to @SanDiegoLiving and @DoMoreCharity for posting the SCOTUS brief and the research paper. Both of them are great reads. IMO AMRN has SCOTUS and Hikma boxed in like a turtle’s pecker. My main concern is; I can’t wrap my head around why SCOTUS would agree to take this case at this stage. I smell a 🐀 😎

1 · Reply

DoMoreCharity Mar. 21 at 3:47 PM

$AMRN https://papers.ssrn.com/sol3/papers.cfm?abstract_id=6427020

1 · Reply

bennfine Mar. 21 at 11:20 AM

$AMRN could hikma execs be shorting?? Wouldn't take too much money to manipulate.

0 · Reply

w1chef Mar. 21 at 3:52 AM

$AMRN from ChatGPT . They provide good summary but for the timing, it says For this case (No. 24-889) Given the timeline: Cert was granted during the current Term (Oct 2025–June 2026) This respondent brief is dated March 20, 2026 👉 That strongly suggests: The case will likely be argued in April 2026 (late in the Term), or Possibly carried over to the next Term (starting Oct 2026) if not scheduled in time

1 · Reply

SanDiegoLiving Mar. 21 at 12:26 AM

$AMRN 🚨 AMARIN SUPREME COURT BRIEF IS UP 🚨 A nice 63 pages of Friday reading starts now. I'll drop my opinion/analysis on here soon for you guys. https://www.supremecourt.gov/DocketPDF/24/24-889/401523/20260320195333332_2026.03.20%20Amarin%20-%20Merits%20Response%20Brief.pdf

4 · Reply

biffermeister Mar. 21 at 12:18 AM

$AMRN TGIF amarinites. always liked this song and it fits here too... https://www.youtube.com/watch?v=kKySE1Ukupg

0 · Reply

MorrisBorris2Duex Mar. 20 at 8:14 PM

$AMRN beer may not be enough tonight.

1 · Reply

CaptBeer Mar. 20 at 8:09 PM

$AMRN I’m buying more next paycheck. BTW, BEER GOOD $AMRN GOOD. 🍺🍺😎

1 · Reply

revivedfossil Mar. 20 at 7:12 PM

$AMRN ugh

0 · Reply

VascepaBID Mar. 20 at 1:24 AM

$AMRN After the SC ruling, can this whole wait and see strategy come to an end? Will this put a final value on the Co/ drug or will they move on to obtaining a new indication to put us back in the "wait and see" if the trial goes well? So frustrating.

1 · Reply

Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript

Feb 23, 2026, 8:00 AM EST - 26 days ago

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Jan 16, 2026, 2:44 PM EST - 2 months ago

US Supreme Court to hear 'skinny label' patent fight involving Amarin

Jan 9, 2026, 7:00 AM EST - 2 months ago

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

Nov 9, 2025, 4:15 PM EST - 4 months ago

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Nov 3, 2025, 8:30 AM EST - 4 months ago

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Oct 29, 2025, 10:21 AM EDT - 5 months ago

Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript

Oct 14, 2025, 8:00 AM EDT - 5 months ago

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Sep 29, 2025, 5:52 PM EDT - 6 months ago

Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom

Aug 31, 2025, 8:30 AM EDT - 7 months ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 30, 2025, 8:30 AM EDT - 7 months ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Aug 25, 2025, 8:00 AM EDT - 7 months ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Jul 30, 2025, 2:06 PM EDT - 8 months ago

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:00 AM EDT - 8 months ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 8 months ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jun 24, 2025, 7:05 AM EDT - 9 months ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

May 7, 2025, 11:01 AM EDT - 11 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:15 PM EDT - 11 months ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 11 months ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 14, 2025, 10:02 AM EDT - 1 year ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO ALMS CCO ECX HZO NUTX

Apr 9, 2025, 7:30 AM EDT - 1 year ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 1 year ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 1 year ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 1 year ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 12, 2025, 10:30 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:00 AM EST - 1 year ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN

Oct 30, 2024, 8:50 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 1 year ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 2 years ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 10:43 AM EDT - 2 years ago

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 2 years ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 2 years ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 2 years ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

dayton91 Mar. 21 at 6:17 PM

1 · Reply

DoMoreCharity Mar. 21 at 3:47 PM

$AMRN https://papers.ssrn.com/sol3/papers.cfm?abstract_id=6427020

1 · Reply

bennfine Mar. 21 at 11:20 AM

$AMRN could hikma execs be shorting?? Wouldn't take too much money to manipulate.

0 · Reply

w1chef Mar. 21 at 3:52 AM

1 · Reply

SanDiegoLiving Mar. 21 at 12:26 AM

4 · Reply

biffermeister Mar. 21 at 12:18 AM

$AMRN TGIF amarinites. always liked this song and it fits here too... https://www.youtube.com/watch?v=kKySE1Ukupg

0 · Reply

MorrisBorris2Duex Mar. 20 at 8:14 PM

$AMRN beer may not be enough tonight.

1 · Reply

CaptBeer Mar. 20 at 8:09 PM

$AMRN I’m buying more next paycheck. BTW, BEER GOOD $AMRN GOOD. 🍺🍺😎

1 · Reply

revivedfossil Mar. 20 at 7:12 PM

$AMRN ugh

0 · Reply

VascepaBID Mar. 20 at 1:24 AM

1 · Reply

MorrisBorris2Duex Mar. 20 at 12:20 AM

$AMRN liking the ah, thinking we may even see 16 tomorrow.

4 · Reply

DoMoreCharity Mar. 20 at 12:03 AM

$AMRN https://www.linkedin.com/posts/mukhtar-khan-2849b2119_mechanism-of-action-of-icosapent-ethyl-think-activity-7440017559426347008--PdK?utm_source=share&utm_medium=member_ios&rcm=ACoAAAappXEBEo5xWglK2bmEx478x0aaRWW4o7I

0 · Reply

DoMoreCharity Mar. 19 at 11:59 PM

$AMRN https://www.facebook.com/share/p/14VmZe8Hw2f/?mibextid=wwXIfr

0 · Reply

declanaidan Mar. 19 at 9:31 PM

$AMRN Crying, waiting, hoping is our lot with Amarin 🥴 https://youtu.be/hE-D8XU6evo?si=SEquF5JSq5wLkmo4

1 · Reply

ians Mar. 19 at 6:10 PM

$AMRN Hey, MRK, wanna take a gander @ Vascepa? Could be a good asset for your ASVCD franchise especially if the SCOTUS rules against Hikma's infringement case 👍☘️💎 "Icosapent ethyl stands out as THE ONLY TG-lowering medication that reduces ASCVD event risk in combination with statin therapy in individuals at high risk of ASCVD with moderate TG elevations who continue to face cardiovascular events despite achieving sufficient LDL-C lowering. As clinicians, we have an opportunity - and responsibility - to utilize this updated guidance to better protect our high-risk patients from additional cardiovascular events." https://finance.yahoo.com/news/amarin-highlights-guideline-recommended-role-123000942.html

1 · Reply

BobGood Mar. 19 at 4:32 PM

$AMRN I like to encash the stocks especially Amarin as much as I can (if the price is right, say $3-4 pre reversal) before the current world crisis (sh*t) hits the fan … Let us see how it evolves in the near future 🤞 But you never know when the luck favors you.. so, let us pray for peace & good things to happen in this world GL

0 · Reply

NilsSB Mar. 19 at 2:33 PM

$AMRN bout that time to increase my holdings and about that time for amarin to buy back shares.

0 · Reply

BobGood Mar. 19 at 1:48 AM

$AMRN Good to see today’s PR .. Can someone quote or refer or an excerpt from the exact highlights of the recommendations exclusively made for IPE … I couldn’t find the same in the PR.. GL

2 · Reply

CaptBeer Mar. 19 at 1:13 AM

$AMRN 2026 AHA/ACC Dyslipidemia Guideline: Major Boost to Amarin v. Hikma Induced Infringement Case: This slide captures why the new guideline is arguably the strongest external event since the Federal Circuit remand. It doesn’t just endorse IPE — it makes the exact patented use (150–499 mg/dL CV risk reduction) the evidence-based standard physicians are now urged to follow. When combined with automatic pharmacy substitution of AB-rated generics, this creates powerful new evidence of inducement under § 271(b). Damages potential increases significantly due to higher infringing script volume, and willfulness arguments get stronger if Hikma doesn’t modify marketing post-guideline.

0 · Reply

DoMoreCharity Mar. 18 at 10:33 PM

$AMRN https://pubmed.ncbi.nlm.nih.gov/41781043/

0 · Reply

CaptBeer Mar. 18 at 8:07 PM

$AMRN New ACC/AHA & EAS/ESC Guidelines for the use of IPE will significantly strengthen Amarin’s infringement case against Hikma. I’ll explain how in detail later this evening after work. I suspect Amarin’s Legal Time is all over this! Stay tuned. 😎

1 · Reply

revivedfossil Mar. 18 at 6:57 PM

$AMRN so friggin aggravating.

1 · Reply

Market Cap	310.81M
Revenue (ttm)	213.65M
Net Income (ttm)	-38.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18.16%
Debt to Equity Ratio	0.00

Volume	82,200
Avg Vol	90,978
Day's Range	N/A - N/A
Shares Out	20.80M
Stochastic %K	7%
Beta	0.86
Analysts	Hold
Price Target	$12.00